FDA Approved: KUVAN — Supplemental Application (BioMarin Pharmaceutical Inc.)

View source ↗

Summary

FDA approved a supplemental application for Kuvan (sapropterin dihydrochloride) from BioMarin Pharmaceutical Inc. to support treatment of phenylketonuria.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Phenylketonuria

Drugs mentioned

• KUVAN (Sapropterin dihydrochloride)

Snippet

SUPPL AP for KUVAN (SAPROPTERIN DIHYDROCHLORIDE)